At their first dose of quadrivalent vaccine for human papillomavirus (HPV), more than 11% of young women aged 13 to 21 years who had never had sexual intercourse were already infected with 1 or more strains of HPV, a study has found.
At their first dose of quadrivalent vaccine for human papillomavirus (HPV), more than 11% of young women aged 13 to 21 years who had never had sexual intercourse were already infected with 1 or more strains of HPV, a study has found.
Researchers evaluated 259 young women recruited from an adolescent primary care clinic of whom 190 (73.4%) were sexually experienced (had had vaginal or anal intercourse). Nine (13%) of the 69 inexperienced study participants reported sexual contact (genital, skin-to-skin contact only). Eight of the sexually inexperienced participants (11.6%) were infected with HPV, as were 133 (70%) of the sexually experienced participants.
Of the sexually inexperienced participants, 2 (2.9%) were infected with HPV-16, 2 (2.9%) with HPV-68, none with HPV-18, and 3 (4.3%) with any vaccine-type HPV. Five patients had more than 1 HPV type (2 with 2 types and 3 with 3 types).
Inexperienced girls and women may have contracted HPV by hand-to-genital or genital skin-to-skin-only contact, the researchers speculate. They note that their study shows that sexually inexperienced girls and young women are vulnerable to HPV infection and it supports recommendations that 11- to 12-year-old girls be targeted for HPV immunization. Vaccination should not be delayed because a girl is not sexually active, they emphasize.
Read other articles in this issue of Special Delivery.
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More